Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D. Wiviott, Marc S. Sabatine, Sabina A. Murphy et al.|New England Journal of Medicine|2018Cited by 6.3k
Effects of Dalcetrapib in Patients with a Recent Acute Coronary SyndromeGregory G. Schwartz, R. Scott Wright, Anders Olsson et al.|New England Journal of Medicine|2012Cited by 2k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialAdrian F. Hernandez, Lauren B. Cooper, Jennifer B. Green et al.|The Lancet|2018Cited by 1.8k
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trialOfri Mosenzon, Itamar Raz, Stephen D. Wiviott et al.|The Lancet Diabetes & Endocrinology|2019Cited by 673
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S. Sabatine, Terje R. Pedersen, Lawrence A. Leiter et al.|The Lancet Diabetes & Endocrinology|2017Cited by 595